Regression of immunoproliferative small intestinal disease after eradication of Helicobacter pylori.
Fischbach
W
W
Medical Department II, Klinikum Aschaffenburg, Akademisches Lohrkrankenhaus, Universität Würzburg, Germany.
Tacke
W
W
Greiner
A
A
Konrad
H
H
Müller-Hermelink
D000328:Adult; D000658:Amoxicillin / Q000627:therapeutic use; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000897:Anti-Ulcer Agents / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D017291:Clarithromycin / Q000627:therapeutic use; D016481:Helicobacter Infections / Q000150:complications / Q000188:drug therapy*; D016480:Helicobacter pylori; D006801:Humans; D007161:Immunoproliferative Small Intestinal Disease / Q000209:etiology*; D018442:Lymphoma, B-Cell, Marginal Zone / Q000382:microbiology / Q000628:therapy; D008297:Male; D009853:Omeprazole / Q000627:therapeutic use; D010406:Penicillins / Q000627:therapeutic use
D000900:Anti-Bacterial Agents; D000897:Anti-Ulcer Agents; D010406:Penicillins; D000658:Amoxicillin; D017291:Clarithromycin; D009853:Omeprazole